Purple Biotech Ltd – ADR (NASDAQ:PPBT) shares are trading lower by 27.7% to $6.02 during Tuesday’s session after the company announced a $2.8 million offering of 472,688 ADS. The stock is also pulling ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
On Monday, Purple Biotech Ltd (NASDAQ:PPBT) reported the final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in ...
26d
Purple Biotech Is Building What Could Be the Next Generation of Cancer Immunotherapy (NASDAQ: PPBT)
Cancer immunotherapy has already had its first revolution. Checkpoint inhibitors changed the treatment landscape by helping the immune system recognize when to attack. Then came a more engineered wave ...
Purple Biotech Ltd. ADR Annual cash flow by MarketWatch. View PPBT net cash flow, operating cash flow, operating expenses and cash dividends.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results